Drug
Trikafta
Trikafta is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_4
1
25%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (50.0%)
Phase 41 (50.0%)
Trials by Status
completed250%
recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
completedphase_4
Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
NCT05743946
completedphase_2
Trikafta in Cystic Fibrosis Patients
NCT03506061
recruiting
Trikafta Exercise Study in Cystic Fibrosis
NCT05279040
recruiting
Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF
NCT05200429
Clinical Trials (4)
Showing 4 of 4 trials
NCT05743946Phase 4
Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
NCT03506061Phase 2
Trikafta in Cystic Fibrosis Patients
NCT05279040
Trikafta Exercise Study in Cystic Fibrosis
NCT05200429
Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4